Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of BI 1015550 in idiopathic pulmonary fibrosis
MOH_2023-05-17_012646Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nerandomilast in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Boehringer Ingelheim. Started Apr 2023; status: active, not recruiting.
02
Drugs
nerandomilast
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on MOH_2023-05-17_012646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-05-17_012646.